ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0318 • ACR Convergence 2025

    Plasma Lipoprotein Subclasses and Risk of Incident Knee Osteoarthritis: A Population-Based Cohort Study

    Cheng Li1, Jing wu2, Yuqing Zhang3, Hongyi He4, Ying Hu5, Jie Wei6, Guanghua Lei6 and Chao Zeng6, 1Xiangya Hospital, Changsha, China (People's Republic), 2Xiangya Hospital, chagnsha, Hunan, China (People's Republic), 3Massachusetts General Hospital, Quincy, MA, 4Xiangya Hospital Central South University, Changsha, China (People's Republic), 5Xiangya School of Public Health Central South University, changsha, China (People's Republic), 6Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic)

    Background/Purpose: Lipoprotein subclasses play diverse roles in health and disease. Although lipoproteins have been implicated in knee osteoarthritis (KOA), the relationship between lipoprotein subclasses and…
  • Abstract Number: 0435 • ACR Convergence 2025

    Comparative Outcomes in Seropositive and Seronegative Rheumatoid Arthritis: A Retrospective Cohort Study

    Ahmad Alomari1, Reem Elmusa2, Nikita Shah3, Miguel Rodriguez4 and Diala Alawneh5, 1UCF- North Florida hospital, Gainesville, FL, 2UCF/ HCA - North florida hospital, Gainesville, FL, 3UCF/HCA Florida North Florida Hospital, Gainesville, FL, 4SIMED Rheumatology, Gainesville, FL, 5University of Florida, Gainesville, FL

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that manifests as either seropositive or seronegative subtypes. Seropositive RA, characterized by the presence of autoantibodies…
  • Abstract Number: 0408 • ACR Convergence 2025

    Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus

    Julia Harris1, Susan Parish2, Michelle Manaskie2 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: There is a profound need to improve outcomes in children with systemic lupus erythematosus (SLE) given this disease is complicated by significant morbidity. Disparities…
  • Abstract Number: 0321 • ACR Convergence 2025

    Per- and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data from the Osteoarthritis Initiative

    Jeffrey Driban1, Lisa Rokoff2, Bing Lu3, Timothy McAlindon4, Charles Eaton5, Mary Roberts6, Diana Mathes7, Colleen Lestician7, Zhijin Carrie Xu7, Zhihua Tina Fan7, Shawn O'Leary7 and Abby Fleisch8, 1University of Massachusetts Chan Medical School, Marlborough, NH, 2Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME, 3UConn Health Center, Newton, MA, 4UMass Chan School of Medicine, Arlington, MA, 5Brown University, Pawtucket, RI, 6Center for Primary Care and Prevention, Kent Hospital, Pawtucket, RI, 7Environmental and Chemical Laboratory Services, Public Health & Environmental Laboratories, New Jersey Department of Health, Ewing, NJ, 8Maine Medical Center; 2. Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook, ME

    Background/Purpose: The prevalence of hand osteoarthritis (OA) has doubled in the United States over the past half century – a finding that cannot be solely…
  • Abstract Number: 0355 • ACR Convergence 2025

    Changes in scanographic bone mineral density in melanoma patients treated with immunotherapy

    Soukayna Baddi1, Suarez Dimitri1, Alexis Ruet1, Theo Van Butsel1, Damiano Cerasuolo1, Jean-Matthieu L’Orphelin1 and Anne-Christine Rat2, 1Caen University Hospital, Caen, France, 2Caen University hospital, UMR 1075 Caen normandy university, Caen, France

    Background/Purpose: The use of immune checkpoint inhibitors (ICIs) is becoming increasingly important in the management of melanoma. However, although ICIs are associated with various immune-related…
  • Abstract Number: 0436 • ACR Convergence 2025

    Why Do Patients with Rheumatic Disease Have MACE and Thrombotic Events?

    Andrea Mazariego and Maria Greenwald, Desert Medical Advances, Rancho Mirage, CA

    Background/Purpose: Patients with rheumatic disease have an increased risk for thrombotic events and major adverse cardiac events (MACE) due to systemic inflammation. Bleeding time is…
  • Abstract Number: 0457 • ACR Convergence 2025

    Pulmonary Profiles: Characterizing Lung Findings in Rheumatoid Arthritis Patients Undergoing Lung Cancer Screening

    Pratyusha Banik1, Melody Andrews1, Sudhakar Pipavath1 and Namrata Singh2, 1University of Washington, Seattle, WA, 2University of Washington, Bellevue, WA

    Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of lung cancer with shared risk factors being heavy smoking history and possibly interstitial…
  • Abstract Number: 0399 • ACR Convergence 2025

    External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis

    Daniel Horton1, Lauren Parlett2, Yuyang Zhu3, Sanika Rege4, Patricia Hoffman5, Daniel Reiff6, Sarah McGuire7, Sonia Pothraj8, Cynthia Salvant9, Lakshmi Moorthy1, Cecilia Huang4, Dawn Koffman4, Matthew Iozzio3, Alicia Iizuka4, Kevin Schott2, Stephen Crystal10, Amy Davidow11, Tobias Gerhard4, Kevin Haynes12, Brian Strom13, Daniel Beachler2 and Carlos Rose14, 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Carelon Research, Inc, Wilmington, DE, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, 4Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, 5Hospital for Special Surgery, New York, NY, 6Boys Town National Research Hospital, Boys Town, 7Department of Obstetrics and Gynecology, Cooper Medical School, Camden, Camden, NJ, 8Washingtonville Pediatrics, Washingtonville, NY, 9Albany Medical Center, Albany, NY, 10Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 11New Jersey Medical School, Newark, NJ, 12Janssen Research & Development, Titusville, NJ, 13Rutgers Biomedical and Health Sciences, New Brunswick, 14Thomas Jefferson University, Wilmington, DE

    Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…
  • Abstract Number: 0488 • ACR Convergence 2025

    Early and Sustained Improvements in Disease Activity and Patient-Reported Outcomes in Patients Treated with Filgotinib for Rheumatoid Arthritis: Up to 2-Year Interim Real-World Data From FILOSOPHY and PARROTFISH

    Jérôme Avouac1, Neil Betteridge2, Karen Bevers3, Gerd Burmester4, Roberto Caporali5, Ouafia Bouzid6, Thomas Debray6, Carole Van der Donckt6, James Galloway7, Susana Romero-Yuste8 and Patrick Verschueren9, 1Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 2Neil Betteridge Associates, London, United Kingdom, 3Sint Maartenskliniek, Nijmegen, Netherlands, 4Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, 6Alfasigma S.p.A., Bologna, Italy, 7King's College London, London, United Kingdom, 8University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Rheumatology, University Hospital Leuven and Skeletal Biology and Engineering Research Centre, KU Leuven, Leuven, Belgium

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients (pts) with rheumatoid arthritis (RA) in Europe. In…
  • Abstract Number: 0383 • ACR Convergence 2025

    Hidden Risk in Low Frailty: Impact of Elixhauser Comorbidities on In-Hospital Mortality Among Osteoporosis Patients — A Nationwide Analysis

    Simran Bhimani1, Anand Reddy Maligireddy2, Sameer Bhimani3, Birju Bhatt4 and Nevena Barjaktarovic5, 1The Wright Center for graduate medical education, Scranton, PA, 2The Wright Center GME, Scarnton, PA, 3The Wright Center for GME, scranton, PA, 4Solara Health NJ, New Jersey, NJ, 5The Wright Center, GME, Scranton, PA

    Background/Purpose: Osteoporosis is a common condition associated with increased morbidity, particularly in older adults. While frailty is a known predictor of adverse outcomes, the independent…
  • Abstract Number: 0455 • ACR Convergence 2025

    Assessment of Pain Outcomes in Pooled Phase 3 Trials of a Selective, Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients With Active Psoriatic Arthritis

    Lihi Eder1, Philip J. Mease2, Vibeke Strand3, Alexis Ogdie4, Atul Deodhar5, Rebecca Haberman6, April Armstrong7, Alice B. Gottlieb8, David Roberts9, Laurie Eliason10, Stefan Varga11, Eleni Vritzali12, Janice Li11 and Laure Gossec13, 1University of Toronto, Toronto, ON, Canada, 2Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, 3Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, 4University of Pennsylvania, Philadelphia, PA, 5Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 6NYU Langone Health, New York, NY, 7University of California Los Angeles, Los Angeles, CA, USA, Los Angeles, CA, 8Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, 9Bristol Myers Squibb, Uxbridge, United Kingdom, 10Bristol Myers Squibb,, Princeton, NJ, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, Boudry, Switzerland, 13Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France

    Background/Purpose: Patients rate pain as one of the most important aspects of psoriatic arthritis (PsA). Pain signaling involves a series of cytokines, including those downstream…
  • Abstract Number: 0463 • ACR Convergence 2025

    Synovial fluid is a robust biomarker of synovial tissue inflammation in rheumatoid arthritis

    Solana Cushing1, Susan Goodman2, Michael Parides1, Hadeel Abdul-Rehman1, Daniel Ramirez2, Edward DiCarlo2, Kristine Carandang3, Renee Davis4, Rebecca Blank5, Laura Donlin1, Anna Helena Jonsson6, Amit Lakhanpal2, Bella Mehta7, Dana Orange8 and Melanie smith2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 3Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 4New York, New York, NY, 5NYU Langone Health, New York, NY, 6University of Colorado School of Medicine, Aurora, CO, 7Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, 8The Rockefeller University, New York, NY

    Background/Purpose: Synovial tissue pathotype may indicate treatment response in RA, but synovial biopsies are not widely available. Synovial fluid (SF) is a promising surrogate. We…
  • Abstract Number: 0500 • ACR Convergence 2025

    Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers

    Sama Hajizadeh1, Tarun Sharma1, Peri Newman2, Julio Hernandez2, Rayford June3, Erik Lehman2, Nicole Wilson1, Nancy Olsen4 and Sharon Banks5, 1Allegheny Health Network, Pittsburgh, PA, 2Penn State Health/ Penn State College of Medicine, Hershey, PA, 3Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, 4Penn State University/Milton S Hershey, Hershey, PA, 5Penn State Milton S. Hershey Medical Center, Hershey, PA

    Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
  • Abstract Number: 0487 • ACR Convergence 2025

    Efficacy of sarilumab in patients with rheumatoid arthritis of different disease activity at treatment initiation: a post-hoc analysis of a Phase 3 trial of sarilumab in Japan

    Hideto Kameda1, Toshiya Takahashi2, Naoki Soeda2 and Yoshiya Tanaka3, 1Department of Internal Medicine, Toho University, Tokyo, Japan, 2Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, 3University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: The efficacy and safety of sarilumab (SAR) and methotrexate (MTX) in patients (pts) in Japan with moderate-to-severely active rheumatoid arthritis (RA) and inadequate response…
  • Abstract Number: 0327 • ACR Convergence 2025

    Structural Severity Assessment of Hand Osteoarthritis Using Radiomic Analysis: Correlation with the Kellgren-Lawrence Score – Results from the DIGICOD Cohort

    Laetitia Perronne1, SELLAM JEREMIE2, Antoine Decoux3, Loïc Duron4, Constance de Margerie5, Maxime Dougados6, Simo Saarakala7, Emmanuel Maheu8, Michel Crema8, Anne Miquel8, Francis BERENBAUM9, Armelle Arnoux3, Jean Denis Laredo10 and Laure Fournier3, 1Northwestern University, Chicago, IL, 2Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-75012 Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France., Paris, France, 3Université paris Cité, Paris, France, 4Hôpital Fondation Adolphe de Rothschild, Paris, France, 5Hôpital Saint Louis, Paris, France, 6Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, 7University of Oulu, Oulu, Finland, 8Hôpital Saint Antoine, Paris, France, 9Sorbonne University/Inserm/AP-HP/4Moving Biotech, Paris, France, 10Hôpital Lariboisière, Paris, France

    Background/Purpose: Radiomics involves the high-throughput extraction of quantitative data from medical imaging. This study aimed to develop a radiomic analysis pipeline applied to hand radiographs…
  • « Previous Page
  • 1
  • …
  • 38
  • 39
  • 40
  • 41
  • 42
  • …
  • 2616
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology